Background {#Sec1}
==========

Lung cancer, a highly invasive, rapidly metastasizing cancer, accounting for more than one million deaths each year, has been the leading cause of cancer deaths worldwide for decades \[[@CR1]\]. Rapidly developing radiological techniques and strengthened consciousness of health screening result in an increased numbers of lung cancer patients diagnosed at early stage. Early-stage lung cancer patients are expected to have a better prognosis compared with those at late stage \[[@CR2]\]. However, significant heterogeneity has been observed for clinical outcomes among the early-stage patients, which may have molecular mechanisms not well understood yet \[[@CR3]\]. Epigenetic alterations---particularly methylation in target organ tissues---is a potential causation of this phenomenon \[[@CR4]\].

Of particular interest, methylation changes at histone demethylase *KDM* gene family are broadly involved in cancer development \[[@CR5], [@CR6]\]. Because methylation is reversible, it provides a source of potential biomarkers and therapeutic targets in cancer \[[@CR7], [@CR8]\]. Most recent publications show a great potential of epigenetic modifiable agencies in cancer therapy \[[@CR9], [@CR10]\]. HumanN6-methyllysine residue demethylation is catalyzed by two distinct subfamilies of demethylases---the flavin-dependent *KDM1* subfamily and the JmjC-domain containing *KDM2-*8 subfamily, which regulate the chromatin state at specific loci, and impact gene expression, DNA repair, DNA replication, and genome stability \[[@CR6]\]. Emerging evidence connects *KDMs* to cancers, including lung cancer \[[@CR11]--[@CR17]\]. DNA methylation is an important gene regulator that provides epigenetic therapeutic targets in cancer. However, to date, no studies have examined the role of DNA methylation in *KDM* demethylase genes and its relationship to clinical outcomes of lung cancer patients.

Therefore, we performed a large-scale association analysis between somatic DNA methylation in *KDM* gene family members and overall survival of non-small cell lung cancer (NSCLC) patients. The study was performed in a discovery set combining four independent Caucasian populations, followed by an independent replication in the data from The Cancer Genome Atlas (TCGA).

Methods {#Sec2}
=======

Lung cancer study populations {#Sec3}
-----------------------------

### Harvard {#Sec4}

The Harvard Lung Cancer Study cohort was described previously \[[@CR18]\]. Briefly, all cases were recruited at Massachusetts General Hospital (MGH) since 1992 and were newly diagnosed, histologically confirmed primary NSCLC. Snap-frozen tumor samples were collected from NSCLC patients during curative surgery with complete resection. There were151 early-stage (TNM stage I, II) cases selected for this study which had complete survival information. Tumor DNA was extracted from 5-μm-thick histopathologic sections. Each specimen was evaluated by an MGH pathologist for amount (tumor cellularity \> 70%) and quality of tumor cells and histologically classified using WHO criteria.

### Spain {#Sec5}

Study population was reported previously \[[@CR19]\]. In brief, tumors were collected by surgical resection from patients who provided consent and under approval by the institutional review boards. The median clinical follow-up was 7.2 years.

### Norway {#Sec6}

As described previously \[[@CR20]\], participants were patients with operable lung cancer tumors who were seen at Oslo University Hospital-Riks hospitalet, Norway, from 2006 to 2011. Only early-stage (stage I, II) patients were selected for the current study.

### Sweden {#Sec7}

Tumor tissue specimens were collected from patient's early-stage lung cancer who underwent operation at the Skane University Hospital, Lund, Sweden \[[@CR21]\].

### TCGA {#Sec8}

We used The Cancer Genome Atlas (TCGA) resources for validation, including 332 early-stage lung adenocarcinomas (AC) and 285 early-stage squamous cell carcinomas (SCC) which had survival information and common covariates. Level-1 HumanMethylation450 DNA methylation data (image data) of each patient were downloaded on October 01, 2015.

Quality control process for DNA methylation data {#Sec9}
------------------------------------------------

DNA methylation was assessed using Illumina Infinium HumanMethylation450 BeadChips (Illumina Inc., San Diego, CA, USA). Raw image data were imported into Genome Studio Methylation ModuleV1.8 (Illumina Inc.) to calculate methylation signals and to perform normalization, background subtraction, and quality control. Unqualified probes were excluded, if they fit the following quality control (QC) criteria: (i) failed detection (*P* \> 0.05) in ≥ 5% samples, (ii) coefficient of variance (CV) \< 5%, (iii) methylated or unmethylated in all samples, (iv) common single nucleotide polymorphisms located in probe sequence or in 10-bp flanking regions, (v) or cross-reactive probes \[[@CR22]\]. Samples with \> 5% undetectable probes were excluded. Methylation signals were further processed for quantile normalization, type I and II correction, and batch effects adjustment using *ComBat* correction \[[@CR23], [@CR24]\]. Those QC and normalization processes were performed at each site separately using the same R code with identical settings. In addition, the site information was included as one of the covariates in the following models to control for potential site heterogeneity. Details of QC processes are described in Additional file [1](#MOESM1){ref-type="media"}: Figure S1.

Gene expression data {#Sec10}
--------------------

In the TCGA cohort, all 332 AC and 285 SCC early-stage patients had complete mRNA sequencing data. TCGA mRNA sequencing data processing and quality control was done by the TCGA workgroup. Raw counts were normalized using RNA Sequencing by Expectation Maximization (RSEM). Level-3 (gene level) gene quantification data were downloaded from TCGA data portal and were further checked for quality. Expression of *KDM* genes was extracted and log~2~ transformed before analysis.

Statistical analysis {#Sec11}
--------------------

Continuous variables were summarized as mean ± standard deviation (SD); categorical variables were described as *n* (%). Ranger, a weighted version of random forest for controlling for the potential confounders, was employed in discovery and validation set, respectively, to evaluate the importance of each individual methylation CpG site \[[@CR25], [@CR26]\]. A weight of 100% was given to each covariate to ensure a 100% chance to be selected into each tree. Variable importance score (VIS) for each methylation site was estimated and ranked in a descending order. CpG sites that were in top 5% in both discovery and validation set were identified as candidates and carried forward for traditional Cox regression.

The candidate methylation probes were further evaluated by Cox regression with adjustment for covariates including age, gender, smoking status, and stage. Results were described as hazard ratio (*HR*) and 95% confidence interval (95%CI) per 1% increment of methylation. Multiple testing corrections were performed using false discovery rate method (FDR; measured by FDR-*q* value) among results from discovery set. The sites with FDR-*q* ≤ 0.05 in discovery set were, in turn, validated in TCGA samples, with a statistical significance level of 0.05. Further, correlations between the DNA methylation of the validated sites and corresponding gene expression level was evaluated by linear regression using TCGA data. Only TCGA samples had both epigenome and transcriptome data, so the methylation-expression analysis was only performed in TCGA cohort.

In addition, flexible criteria were hired for further exploration: (1) CpG sites that were in top 10% in both discovery and validation set were identified as candidates, (2) candidates with FDR-*q* ≤ 0.1 in discovery set, and (3) *P* value ≤ 0.05 in validate set. Classification and regression tree (CART) was used to identify clusters with heterogeneous survival outcome. Kaplan-Meier method was used to illustrate the survival curves of different clusters.

All analyses were performed in R Version 3.2.4 (The R Foundation).

Results {#Sec12}
=======

We analyzed 393 DNA methylation probes (Additional file [2](#MOESM2){ref-type="media"}: Table S1) in 17 *KDM* gene family members located on autosomal chromosomes (Additional file [3](#MOESM3){ref-type="media"}: Table S2). Analysis was performed on 1230 tumor DNA samples from early-stage NSCLC patients recruited from five lung cancer study cohorts. Demographics and clinical characteristics are described in Table [1](#Tab1){ref-type="table"}. Figure [1](#Fig1){ref-type="fig"} shows a flow chart for overall analysis. Samples from the Harvard, Spain, Norway, and Sweden studies were combined together for discovery.Table 1Demographic and clinic pathological descriptions for study populationsVariablesDiscovery setValidation setHarvard\
(*N* = 151)Spain\
(*N* = 226)Norway\
(*N* = 133)Sweden\
(*N* = 103)All\
(*N* = 613)TCGA\
(*N* = 617)Age (years), mean ± SD67.67 ± 9.9265.67 ± 10.5865.52 ± 9.3467.54 ± 9.9966.44 ± 10.0866.51 ± 9.47Gender, *n* (%)\* Female67 (44.37)105 (46.46)71 (53.38)54 (52.43)297 (48.45)255 (41.33) Male84 (55.63)121 (53.54)62 (46.62)49 (47.57)316 (51.55)362 (58.67)Smoking status, *n* (%)\* Never18 (11.92)30 (13.57)17 (12.78)18 (17.48)83 (13.65)55 (9.18) Former81 (53.64)120 (54.30)74 (55.64)54 (52.43)329 (54.11)376 (62.77) Current52 (34.44)71 (32.13)42 (31.58)31 (30.10)196 (32.24)168 (28.05) Unknown0500518TNM stage, *n* (%)\* I104 (68.87)183 (80.97)93 (69.92)95 (92.23)475 (77.49)393 (63.70) II47 (31.13)43 (19.03)40 (30.08)8 (7.77)138 (22.51)224 (36.30)Histology, *n* (%)\* Adenocarcinoma (AC)96 (63.58)183 (80.97)133 (100.00)80 (77.67)492 (80.26)332 (53.81) Squamous cell carcinoma (SCC)55 (36.42)43 (19.03)0 (0.00)23 (22.33)121 (19.74)285 (46.19)Chemotherapy, *n* (%)\* No142 (94.04)177 (90.77)102 (76.69)67 (90.54)488 (88.25)194 (76.98) Yes9 (5.96)18 (9.23)31 (23.31)7 (9.46)65 (11.75)58 (23.02) Unknown03102960365Radiotherapy, *n* (%) No132 (87.42)184 (94.36)132 (99.25)74 (100.00)522 (94.39)239 (94.84) Yes19 (12.58)11 (5.64)1 (0.75)0 (0.00)31 (5.61)13 (5.16) Unknown03102960365Adjuvant therapy, *n* (%)\* No127 (84.11)168 (86.15)101 (75.94)67 (90.54)463 (83.73)187 (74.21) Yes24 (15.89)27 (13.85)32 (24.06)7 (9.46)90 (16.27)65 (25.79) Unknown03102960365Survival year, month Median (95%CI)6.66 (5.41--7.87)7.12 (5.06--9.63)7.36 (6.77--7.95)^\*^7.39 (4.98--9.12)7.39 (6.50--8.23)4.54 (3.68--5.41) Dead, *n* (%)122 (80.79)101 (44.69)42 (31.58)58 (31.58)323 (52.69)142 (23.01)\*Statistically significant difference (*P* ≤ 0.05) was observed between combined discovery set and validation set (TCGA)Fig. 1Analysis work flow. Adenocarcinoma and squamous cell carcinoma samples from Harvard, Spain, Norway, and Sweden cohorts were used for the discovery phase of analysis. Data from The Cancer Genome Atlas (TCGA) were used for validation. Ranger is a weighted version of random forest for controlling for the covariates including age, gender, smoking status, and histological stage. Variable importance score (VIS) was estimated for each CpG site and was ranked in descending order. CpG sites ranked in top 5% in both discovery and validation sets were selected for further evaluation by Cox regression. Multiple testing correction by false discovery rate (FDR) method was used if necessary

Among AC samples, only one common CpG site, cg07584494 in *KDM4B*, was identified of which the importance ranked in the top 5% both in discovery and validation sets (Fig. [2](#Fig2){ref-type="fig"}). This CpG was further evaluated by Cox regression, meanwhile, did not reach the stringent criteria of *P* value ≤ 0.05 in both discovery and validation sets.Fig. 2Ranger in discovery (**a**) or validation (**b**) in adenocarcinomas. Weighted random forest (Ranger, where confounders like age, gender, smoking status, and stage are adjusted with given 100% weight) was employed in discovery phase (**a**) and validation set (**b**) to evaluate the importance of variables. Ranger provides VIS (variable importance score) for each methylation sites. Variables that were in top 5% (red lollipop) or top 10% (yellow lollipop, a flexible criterion) in both discovery phase (**a**) and validation (**b**) would be carried forward

For SCC samples, the two common probes, cg11637544 within the first exon of *KDM2A* and cg26662347 at TSS200 region of *KDM1A*, were ranked in the top 5% in both discovery and validation sets (Fig. [3](#Fig3){ref-type="fig"}). These two CpG sites were further evaluated by Cox regression in discovery set and showed a significant association with SCC patients' survival \[cg11637544~*KDM2A*~, hazard ratio (*HR*) per 1% methylation increment = 1.38, 95% confidence interval (95%CI) 1.15--1.66, *P* = 0.0006, FDR*-q* = 0.0011; cg26662347~*KDM1A*~, *HR* = 2.12, 95%CI 1.26--3.57, *P* = 0.0045, FDR-*q* = 0.0090\]. Both CpG sites were replicated with statistical significance in validation set from TCGA (*HR*~cg11637544~ = 1.26, 95%CI 1.05--1.52, *P* = 0.0136; *HR*~cg26662347~ = 1.75, 95%CI 1.16--2.64, *P* = 0.007). Meta-analysis combining the evidences from the discovery and validation sets further showed a stronger association between worse SCC patient's survival and hyper-methylation at cg11637544~*KDM2A*~ (*HR* = 1.32, 95%CI, 1.16--1.50, *P* = 1.1 × 10^−4^; Fig. [4a](#Fig4){ref-type="fig"}) and at cg26662347~*KDM1A*~ (*HR* = 1.88, 95%CI, 1.37--2.60, *P* = 3.7 × 10^−3^; Fig. [4b](#Fig4){ref-type="fig"}). Furthermore, altered DNA methylation at sites cg11637544~*KDM2A*~ (*r* = 0.37, *P* = 1.3 × 10^−10^) (Fig. [4c](#Fig4){ref-type="fig"}) and cg26662347~*KDM1A*~ (*r* = 0.25, *P* = 1.5 × 10^−5^) (Fig. [4d](#Fig4){ref-type="fig"}) were positively correlated with the corresponding gene expression.Fig. 3Ranger in discovery (**a**) or validation (**b**) in squamous cell carcinomas. Weighted random forest (Ranger, where confounders like age, gender, smoking status, and stage are adjusted with given 100% weight) was employed in discovery phase (**a**) and validation set (**b**) to evaluate the importance of variables. Ranger provides VIS (variable importance score) for each methylation sites. Variables that were in top 5% (red lollipop) or top 10% (yellow lollipop, a flexible criterion) in both discovery phase (**a**) and validation (**b**) would be carried forwardFig. 4Association between DNA methylation at sites cg11637544 in *KDM2A* and cg26662347 in *KDM1A* with overall survival of squamous cell carcinomas and correlation between these two sites and their corresponding gene expression. Fixed-effects meta-analysis was used to combine the results from discovery and validation sets for squamous cell carcinomas (SCC) (**a** cg11637544~*KDM2A*~; **b** cg26662347~*KDM1A*~). *I*^2^and corresponding *P* value were used to evaluate heterogeneity across studies. DNA methylation level was categorized to six quantiles, and box plot for gene expression was drawn for each quantile. Pearson correlation was used to estimate the correlation coefficient (*r*) and the *P* value; gene expression was log2 transformed before analysis (**c** cg11637544~*KDM2A*~; **d** cg26662347~*KDM1A*~)

In addition to the stringent criteria, we also comprehensively explored the data using Ranger with relatively flexible criteria, followed by survival classification tree analysis which can consider both linear and non-linear patterns, and both individual and interaction effects of CpG sites simultaneously (Additional file [4](#MOESM4){ref-type="media"}: Figure S2). CpG sites of which the variable importance score ranked in the top 10% in both discovery and validation set were selected, including seven CpG sites for AC samples (Fig. [2](#Fig2){ref-type="fig"}) and five for SCC samples (Fig. [3](#Fig3){ref-type="fig"}). Among AC cases, seven CpG sites as well as covariates were used to build a survival classification tree using the merged data of discovery and validation sets (Fig. [5a](#Fig5){ref-type="fig"}). Four clusters were identified with significantly different survival curves (Fig. [5b](#Fig5){ref-type="fig"}) and outcome (Fig. [5c](#Fig5){ref-type="fig"}). Among these seven CpG sites, none showed a correlation with corresponding gene's expression. Similarly, among SCC cases, five CpG sites, three of which were newly identified, and covariates were used to build the classification tree (Fig. [6a](#Fig6){ref-type="fig"}), which identified five clusters and statistically distinguished patient's survival (Fig. [6b](#Fig6){ref-type="fig"}, [c](#Fig6){ref-type="fig"}). Among the three newly identified CpG sites for SCC samples (Additional file [4](#MOESM4){ref-type="media"}: Figure S2), two of which were correlated with their corresponding gene expression with statistical significance (*r*~cg00121158~ = 0.24, *P*~cg00121158~ = 4.38 × 10^−5^; *r*~cg06615743~ = − 0.17, *P*~cg06615743~ = 0.004; Additional file [5](#MOESM5){ref-type="media"}: Figure S3A-B).Fig. 5Survival classification tree for adenocarcinomas. Survival classification tree was built with seven CpG sites as well as covariates using the merged data of discovery and validation sets among adenocarcinoma cases (**a**), which identified five clusters with significantly different survival curves (**b**). Cox regression was used to compare the outcomes among clusters (cluster 4 as reference) and represented by hazard ratio (*HR*), 95% confidence interval (95%CI), and the *P* value (**c**)Fig. 6Survival classification tree for squamous cell carcinomas. Survival classification tree was built with five CpG sites as well as covariates using the merged data of discovery and validation sets among adenocarcinoma cases (**a**), which identified four clusters with significantly different survival curves (**b**). Cox regression was used to compare the outcomes among clusters (cluster 4 as reference) and represented by hazard ratio (*HR*), 95% confidence interval (95%CI), and the *P* value (**c**)

Discussion {#Sec13}
==========

Several non-hypothesis-based epigenome-wide studies have analyzed lung cancer prognosis \[[@CR19]--[@CR21]\] and have identified several potential epigenetic biomarkers to help better understand the etiology of NSCLC. To the best of our knowledge, this is the first population-based study integrating five independent cohorts that suggested the relationship between tumor DNA methylation alterations at the *KDM* gene family members and NSCLC overall survival. The results expand our current understanding of the *KDM* gene family in lung cancer etiology.

DNA methylation surrounding the transcriptional start site (TSS) has been investigated extensively \[[@CR27]\]; generally, hyper-methylation blocks transcription initiation and reduces gene expression \[[@CR27], [@CR28]\]. However, DNA methylation at cg11637544 in the first exon of *KDM2A* and at cg26662347 in the 200-kb TSS region of *KDM1A* elevates corresponding expression in tumor tissues. The function of gene body methylation remains unclear. However, functional elements could be in the gene body and could modulate expression through enhancers, transcription factor binding sites, and repetitive elements \[[@CR29]\]. Gene body DNA methylation may maintain nucleosome stabilization in transcribed regions and increase transcriptional efficiency either by elongation or by splicing, which, in turn, leads to altered outcomes \[[@CR30]\]. Although promoter-associated hyper-methylation mostly downregulates gene expression, a small part of methylation surrounding TSS region upregulates expression \[[@CR31]\]. This phenomenon may be mediated by affecting the binding activity of upstream transcription factors \[[@CR32]\], which warrants further well-designed functional studies.

As previously reported, overexpression of *KDM1A* and *KDM2A* in NSCLC cells increases cell proliferation and invasiveness and promotes cancer metastasis \[[@CR12], [@CR13]\]. Here, we provided further evidence that those associations appear to be generalizable to patient population. However, functional studies are needed to evaluate the mechanisms that underlie the associations between methylation alterations and survival and the mediating pathway affecting gene transcription. Nevertheless, no promising individual CpG site was identified for adenocarcinoma patients following the stringent criteria, which may due to underlying epigenetic heterogeneity between adenocarcinomas and squamous cell carcinomas \[[@CR33], [@CR34]\].

In addition, a comprehensive survival classification tree analysis were also performed to further explore the data by including more potentially associated CpG sites, which identified clusters with significantly different clinical outcome for both adenocarcinomas and squamous cell carcinomas. More *KDM* genes, including *KDM4B*, *KDM2B*, and *KDM4A* for adenocarcinomas and *KDM2B*, *KDM4C*, and *KDM4B* for squamous cell carcinomas, appear to be associated with patients' survival. So far, *KDM2B* has been involved in mechanisms, independently or interactively with microRNAs, for cancers of the blood \[[@CR35]\], pancreas \[[@CR36]\], breast \[[@CR37]\], or stomach \[[@CR38]\]. However, the direct impact of *KDM2B* DNA methylation on SCC survival is not well understood and therefore is an area that needs further exploration. *KDM4* histone demethylases is emerging as key regulatory modifiers to histone trimethylated residues that have an important role in cancer development and as a potential therapeutic targets \[[@CR39]\]. *KDM4A* is related to mTOR inhibitor sensitivity in SCC patients and impacts copy gains of drug-resistant regions in the genome \[[@CR17], [@CR40]\]. *KDM4B* encodes a DNA damage response protein that confers a survival advantage following γ-irradiation \[[@CR41]\]. *KDM4C* inhibition by curcuminoids is an adjuvant therapy that can benefit colon cancer patients \[[@CR42]\]. However, methylation signals in *KDM4* family members are not individually associated with NSCLC survival, which indicates that there may have interactions of *KDM4* and the other elements.

A major strength of this study is that we used weighted random forest (Ranger) to filter DNA methylation signals. Random forest (RF) is powerful in handling high-dimensional genetic data, but false positive or spurious association may occur if confounding factors are not corrected \[[@CR43]\]. In Ranger, there is a parameter from 0 to 1 that represents the probability of variables selected for splitting the tree \[[@CR26]\]. If the weight of covariate is given a value of 1, this covariate would be involved in each tree with 100% chance, and thus be controlled. In addition, survival classification tree, a nonparametric and decision-tree-based data mining approach, was used which can improve statistical power and indicate potential interactions between the CpG sites in this study \[[@CR44], [@CR45]\]. However, further studies need to be done to validate authenticity and how they interact, which is another area that needs further exploration.

We acknowledge some limitations in our study. First, the positive association between methylation and corresponding gene expression lacks biological evidence. The association should be interpreted with caution, and thus warrants further functional experiments. Second, the censored rate of TCGA cohort is relatively high. Early-stage NSCLC patients could be followed longer to obtain more precise estimates in future. In addition, clinical therapy information after surgery is under informative and not included in this study. Finally, our study did not include other races rather than Caucasian. The findings of this study should be interpreted with caution among other populations. Further studies are needed to investigate their possible differences among multiple ethnicities.

Conclusions {#Sec14}
===========

In conclusion, this study highlights the role of somatic epigenetic alterations of *KDM* gene family members on NSCLC overall survival. The findings indicate potential dynamic and reversible therapeutic targets for lung cancer patients and may suggest a high-risk early-stage NSCLC population for adjuvant therapies.
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Additional file 1:**Figure S1.** Quality control processes for DNA methylation chip data. Quality control measures and exclusion criteria as applied to Harvard, Spain, Norway, Sweden, and The Cancer Genome Atlas (TCGA) sample cohorts. (PDF 642 kb) Additional file 2:**Table S1.** Annotation of CpG sites in KDM gene family. (PDF 677 kb) Additional file 3:**Table S2.** Distributions of CpG sites in KDM genes. (PDF 153 kb) Additional file 4:**Figure S2.** Analysis work flow. Adenocarcinoma and squamous cell carcinoma samples from Harvard, Spain, Norway, and Sweden cohorts were used for the discovery phase of analysis. Data from The Cancer Genome Atlas (TCGA) were used for Validation. Ranger is a weighted version of random forest for controlling for the covariates including age, gender, smoking status, and histological stage. Variable importance score (VIS) was estimated for each CpG site and was ranked in descending order. CpG sites ranked in top 10% in both discovery and validation sets were selected for further evaluation by Cox regression. Multiple testing correction by false discovery rate (FDR) method was used if necessary. (PDF 357 kb) Additional file 5:**Figure S3.** DNA methylation probes identified by flexible criterion in squamous cell carcinoma and their correlation with corresponding gene expression. Three more sites were identified in SCC samples under flexible criterion: cg06646494 in *KDM2B*, cg00121158 in *KDM4C*, and cg06615743 in *KDM4B*. The cg00121158 (A) and cg06615743 (B) showed a statistical correlation with the corresponding gene expression. DNA methylation level was categorized to six quantiles and box plot for gene expression was drawn for each quantile. Pearson correlation was used to estimate the correlation coefficient (r) and the *P* value, Gene expression was log2 transformed before analysis. (PDF 571 kb)
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